Regulatory Decision Summary for Evicel

Review decision

The Regulatory Decision Summary explains Health Canada’s decision for the product seeking market authorization. The Regulatory Decision Summary includes the purpose of the submission and the reason for the decision.

Product type:


Medicinal ingredient(s):

Fibrin Sealant Kit

Therapeutic area:

Hemostatic Agent

Type of submission:

Supplement to a New Drug Submission (SNDS)

Control number:

What was the purpose of this submission?


The purpose of this SNDS was to seek a new indication for Evicel for the sealing of the dural suture line in specific conditions which is an addition to the present indication for use in surgery as supportive treatment to standard surgical procedures in establishing hemostasis.


Why was the decision issued?


Evicel is a fibrin sealant authorized for support of hemostasis in surgery. The present indication expands the indication to the support of dural suturing to obtain a water tight closure. Evicel does not contain tranexamic acid, thus avoiding its potential for neurotoxicity. Risk mitigation has been addressed for the product in previous submissions, most recently in regard to the risk of air/gas embolism when spraying under pressure. The use of the product in the indicated neurosurgical settings for sealing the dural suture line did not result in unexpected adverse events. Monitoring will continue as use increases.

The pivotal clinical trial shows that application following suturing of the dura is more effective than additional sutures in preventing further leakage when assessed at the time of surgery in ideal suturing conditions. The benefits are not known, however, in other dural suturing situations where a sealant might be considered, including if the size of the defect is >2mm, if dural patches are used or following radiation or chemotherapy. These limitations are indicated in the updated Product Monograph in the "Use in Neurosurgery" section.

The serious adverse events (SAEs) when assessed up to 30 days following surgery in the Evicel group and the suture group are comparable if rhinorrhea is excluded from the Evicel group. Other SAEs include hygroma, cerebrospinal fluid (CSF) leaks, meningitis. In some cases it is uncertain whether the SAE should be attributed to the study product or the intracranial procedure. The small number of adverse events (AEs) and subjects and the different types of intracranial surgeries in the trial make it difficult to assess causality of the AEs.

In summary, the study submitted shows that Evicel is superior to additional sutures in sealing the dural suture line in ideal suturing conditions when assessed at the time of surgery. The risk of adverse events that could be due to later leakage is not clear because of the small number of events and subjects. At this time, the benefit/risk is considered favourable for this indication.


Decision issued

Approved; issued Notice of Compliance in accordance with the Food and Drug Regulations